DiaMedica Therapeutics (DMAC) Total Liabilities (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Total Liabilities for 10 consecutive years, with $6.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 54.95% year-over-year to $6.7 million; the trailing twelve-month figure through Jun 2026 stood at $6.7 million (up 54.95% YoY), and the FY2025 full-year result was $5.3 million, down 6.52% from the prior year.
• Total Liabilities grew to $6.7 million in Q2 2026 per DMAC's latest filing, from $5.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $6.7 million in Q2 2026 and bottomed at $1.4 million in Q1 2022.
• Historically, Total Liabilities has averaged $3.7 million across 5 years, with a median of $3.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities soared 121.41% in 2023, then declined 8.89% in 2024.
• Over 5 years, Total Liabilities stood at $2.6 million in 2022, then gained by 20.83% to $3.1 million in 2023, then surged by 81.34% to $5.6 million in 2024, then dropped by 6.52% to $5.3 million in 2025, then grew by 26.67% to $6.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $6.7 million, $5.8 million, and $5.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.